DENTSPLY SIRONA (NASDAQ:XRAY) Stock Price Expected to Rise, Mizuho Analyst Says

DENTSPLY SIRONA (NASDAQ:XRAY) had its price objective raised by Mizuho from $14.00 to $16.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a “neutral” rating on the medical instruments supplier’s stock. Mizuho’s price target indicates a potential upside of 20.30% from the stock’s previous close.

XRAY has been the subject of several other research reports. Robert W. Baird upped their price objective on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a research note on Friday, February 27th. Stifel Nicolaus set a $13.00 target price on DENTSPLY SIRONA in a report on Thursday, November 6th. Barclays initiated coverage on DENTSPLY SIRONA in a research report on Monday, December 8th. They issued an “underweight” rating and a $12.00 price target for the company. JPMorgan Chase & Co. reduced their price objective on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Friday, November 7th. Finally, Wells Fargo & Company upped their target price on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 27th. Three equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $14.42.

DENTSPLY SIRONA Stock Down 7.1%

Shares of XRAY opened at $13.30 on Monday. The stock has a 50 day moving average price of $12.52 and a 200 day moving average price of $12.47. DENTSPLY SIRONA has a one year low of $9.85 and a one year high of $17.18. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.03 and a current ratio of 1.51. The stock has a market capitalization of $2.66 billion, a price-to-earnings ratio of -4.43, a PEG ratio of 1.68 and a beta of 0.97.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The business had revenue of $961.00 million for the quarter, compared to analyst estimates of $926.40 million. During the same period last year, the firm earned $0.26 EPS. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities research analysts forecast that DENTSPLY SIRONA will post 1.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DENTSPLY SIRONA news, Director Gregory T. Lucier sold 82,200 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $11.14, for a total transaction of $915,708.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.52% of the company’s stock.

Hedge Funds Weigh In On DENTSPLY SIRONA

A number of hedge funds have recently modified their holdings of the business. Parkside Financial Bank & Trust lifted its position in shares of DENTSPLY SIRONA by 620.6% during the second quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 1,477 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in DENTSPLY SIRONA during the 1st quarter worth approximately $26,000. Eurizon Capital SGR S.p.A. acquired a new stake in DENTSPLY SIRONA during the 4th quarter worth approximately $26,000. True Wealth Design LLC boosted its position in DENTSPLY SIRONA by 273.0% in the 2nd quarter. True Wealth Design LLC now owns 2,376 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 1,739 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its stake in shares of DENTSPLY SIRONA by 337.9% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,122 shares in the last quarter. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

DENTSPLY SIRONA News Summary

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Director buying: Gregory T. Lucier significantly increased his stake in Dentsply Sirona, purchasing 27,555 shares on March 2 at ~$14.24 and 22,445 shares on March 3 at ~$14.03 (bringing his reported holdings to ~50,000 shares). Large insider purchases are often viewed as a bullish signal of management confidence. SEC Form 4
• Positive Sentiment: Barrington Research raised its price target to $17 and maintained an “outperform” rating — a bullish analyst action that implies meaningful upside from current levels and can support buying interest. Barrington Research PT Raise
• Neutral Sentiment: Mizuho raised its price target to $16 but kept a “neutral” rating — a PT lift that helps sentiment but the unchanged rating tempers the positive impact. Mizuho PT Update TickerReport
• Neutral Sentiment: Investor access: Management will present at the Leerink Partners Global Healthcare Conference on March 10 — a scheduled investor event that provides an opportunity for management to update guidance and interact with analysts (near-term catalyst if new commentary or data are released). Conference Notice
• Neutral Sentiment: Analyst coverage/targets: Smaller media posts also reported price-target bumps (AmericanBankingNews noted PTs raised to $13 and $14). These incremental upgrades help sentiment but are mixed in magnitude. PT to $13 PT to $14
• Neutral Sentiment: Fundamental note: A Zacks piece flagged international revenue trends as an area to watch; investors assessing XRAY should consider geographic growth dynamics versus company guidance/analyst models. Zacks Analysis
• Neutral Sentiment: Short-interest data appears anomalous (reports show zero shares / NaN changes), suggesting a reporting error rather than a genuine short-squeeze or relief — treat the short-interest updates cautiously. (No reliable link; data appears inconsistent in the filings.)

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.